[go: up one dir, main page]

DK4269444T5 - Multispecifikke antistoffer mod variabel anti-tcr-delta 1 - Google Patents

Multispecifikke antistoffer mod variabel anti-tcr-delta 1 Download PDF

Info

Publication number
DK4269444T5
DK4269444T5 DK23187269.8T DK23187269T DK4269444T5 DK 4269444 T5 DK4269444 T5 DK 4269444T5 DK 23187269 T DK23187269 T DK 23187269T DK 4269444 T5 DK4269444 T5 DK 4269444T5
Authority
DK
Denmark
Prior art keywords
tcr
delta
antibodies against
multispecific antibodies
variable anti
Prior art date
Application number
DK23187269.8T
Other languages
English (en)
Other versions
DK4269444T3 (en
Inventor
Mark Uden
Mihriban Tuna
Natalie Mount
Robert Good
Joshua Freedman
Shefali Bhumbra
Oliver Nussbaumer
Raj Jaysukhlal Mehta
Original Assignee
Gammadelta Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80247426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4269444(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/GB2020/051959 external-priority patent/WO2021032963A1/en
Priority claimed from GBGB2102222.3A external-priority patent/GB202102222D0/en
Priority claimed from GBGB2102224.9A external-priority patent/GB202102224D0/en
Application filed by Gammadelta Therapeutics Ltd filed Critical Gammadelta Therapeutics Ltd
Application granted granted Critical
Publication of DK4269444T3 publication Critical patent/DK4269444T3/da
Publication of DK4269444T5 publication Critical patent/DK4269444T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
DK23187269.8T 2020-08-14 2021-08-14 Multispecifikke antistoffer mod variabel anti-tcr-delta 1 DK4269444T5 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2020/051959 WO2021032963A1 (en) 2019-08-16 2020-08-14 Therapeutic uses of anti-tcr delta variable 1 antibodies
GBGB2102222.3A GB202102222D0 (en) 2021-02-17 2021-02-17 Multispecific anti-TCR delta variable 1 antibodies
GBGB2102224.9A GB202102224D0 (en) 2021-02-17 2021-02-17 Anti-TRC delta variable 1 antibodies
EP23153152.6A EP4218932A3 (en) 2020-08-14 2021-08-14 Multispecific anti-tcr delta variable 1 antibodies

Publications (2)

Publication Number Publication Date
DK4269444T3 DK4269444T3 (en) 2024-08-19
DK4269444T5 true DK4269444T5 (da) 2024-08-26

Family

ID=80247426

Family Applications (2)

Application Number Title Priority Date Filing Date
DK21756070.5T DK4010082T5 (da) 2020-08-14 2021-08-14 Multispecifikke antistoffer mod variabel anti-tcr-delta 1
DK23187269.8T DK4269444T5 (da) 2020-08-14 2021-08-14 Multispecifikke antistoffer mod variabel anti-tcr-delta 1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK21756070.5T DK4010082T5 (da) 2020-08-14 2021-08-14 Multispecifikke antistoffer mod variabel anti-tcr-delta 1

Country Status (18)

Country Link
EP (7) EP4265643B1 (da)
JP (1) JP2023537534A (da)
KR (1) KR20230083267A (da)
CN (1) CN116209456A (da)
AU (1) AU2021323512A1 (da)
BR (1) BR112023002741A2 (da)
CA (1) CA3188682A1 (da)
CO (1) CO2023003009A2 (da)
DK (2) DK4010082T5 (da)
ES (2) ES2943063T3 (da)
FI (2) FI4010082T3 (da)
IL (1) IL300517A (da)
LT (2) LT4269444T (da)
MX (1) MX2023001728A (da)
PL (2) PL4269444T3 (da)
PT (2) PT4269444T (da)
SI (2) SI4269444T1 (da)
WO (1) WO2022034562A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4269444T3 (pl) 2020-08-14 2025-01-13 GammaDelta Therapeutics Limited Wieloswoiste przeciwciała anty-tcr zmienne delta 1
AU2023288542A1 (en) * 2022-06-23 2024-12-19 LAVA Therapeutics N.V. Assay for t cell dependent multispecific compounds
WO2024193459A1 (en) * 2023-03-17 2024-09-26 Nanjing Legend Biotech Co., Ltd. METHODS OF CULTURING Vδ1 T CELLS

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
WO2015063069A1 (en) * 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
EP3623468A1 (en) 2015-06-09 2020-03-18 Lymphact - Lymphocyte Activation Technologies, S.A. Methods for the production of tcr gamma delta+ t cells
DK3368658T3 (da) 2015-10-30 2022-08-01 Cancer Research Tech Ltd Ekspansion af ikke-hæmatopoetiske vævsresidente gamma-delta-T-celler og anvendelser af disse celler
JP7210286B2 (ja) 2016-05-12 2023-01-23 アディセット バイオ， インコーポレイテッド γδＴ細胞集団の選択的増殖方法及びその組成物
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CA3032304A1 (en) 2016-07-29 2018-02-01 New York University Gamma delta t cells as a target for treatment of solid tumors
US10546518B2 (en) 2017-05-15 2020-01-28 Google Llc Near-eye display with extended effective eyebox via eye tracking
JP7356970B2 (ja) 2017-06-25 2023-10-05 システィミューン， インク． 多重特異性抗体とその作製及び使用方法
US10519236B2 (en) 2018-01-23 2019-12-31 New York University Antibodies specific to delta 1 chain of T cell receptor
WO2020060405A1 (en) * 2018-09-19 2020-03-26 Lava Therapeutics B.V. Dual acting cd1d immunoglobulin
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
JP2022519082A (ja) 2019-02-01 2022-03-18 ラヴァ・セラピューティクス・ベー・フェー 新規ｃｄ４０結合抗体
JP2022525435A (ja) 2019-04-08 2022-05-13 メモリアル スローン ケタリング キャンサー センター Ｃｄ１９抗体およびこれを使用する方法
KR20220045980A (ko) 2019-08-16 2022-04-13 감마델타 테라퓨틱스 리미티드 체외 감마 델타 t 세포 집단
WO2021032960A1 (en) 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Novel anti-tcr delta variable 1 antibodies
PL4269444T3 (pl) 2020-08-14 2025-01-13 GammaDelta Therapeutics Limited Wieloswoiste przeciwciała anty-tcr zmienne delta 1
TW202302639A (zh) 2021-02-17 2023-01-16 英商伽馬三角洲療法有限公司 多特異性抗ＴＣＲ δ可變１抗體

Also Published As

Publication number Publication date
ES2993071T3 (en) 2024-12-20
EP4218932A3 (en) 2023-09-27
CN116209456A (zh) 2023-06-02
EP4265643A2 (en) 2023-10-25
FI4269444T3 (fi) 2024-09-20
EP4265642A3 (en) 2024-02-14
EP4269445A2 (en) 2023-11-01
EP4218932A2 (en) 2023-08-02
JP2023537534A (ja) 2023-09-01
LT4269444T (lt) 2024-09-25
DK4010082T5 (da) 2024-08-05
EP4269446A3 (en) 2024-02-14
EP4269444A3 (en) 2024-02-14
EP4269446A2 (en) 2023-11-01
PT4269444T (pt) 2024-09-05
SI4269444T1 (sl) 2024-10-30
WO2022034562A1 (en) 2022-02-17
PL4010082T3 (pl) 2023-05-29
EP4265642A2 (en) 2023-10-25
IL300517A (en) 2023-04-01
ES2943063T3 (es) 2023-06-08
EP4010082B1 (en) 2023-01-25
DK4269444T3 (en) 2024-08-19
PL4269444T3 (pl) 2025-01-13
BR112023002741A2 (pt) 2023-10-10
EP4269445A3 (en) 2024-02-14
AU2021323512A1 (en) 2023-04-13
EP4010082A1 (en) 2022-06-15
DK4010082T3 (da) 2023-04-03
EP4269444B1 (en) 2024-06-26
EP4269446B1 (en) 2024-06-26
MX2023001728A (es) 2023-04-20
KR20230083267A (ko) 2023-06-09
EP4265643A3 (en) 2024-02-14
PT4010082T (pt) 2023-04-26
EP4265643B1 (en) 2024-06-26
CA3188682A1 (en) 2022-02-17
CO2023003009A2 (es) 2023-03-17
FI4010082T3 (fi) 2023-04-04
SI4010082T1 (sl) 2023-04-28
LT4010082T (lt) 2023-03-10
EP4269444A2 (en) 2023-11-01
EP4265642B1 (en) 2024-06-26
EP4269445B1 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
DK3872091T3 (da) Antistoffer mod sars-cov-2
DK4010082T3 (da) Multispecifikke antistoffer mod variabel anti-tcr-delta 1
EP4239011A4 (en) Polyamide
IL310528A (en) Pyrazolopyridinone compounds
CR20230573A (es) ANTICUERPOS ANTI-SIRP-alfa
EP4163107A4 (en) Decorative sheet
IL311043A (en) Anti-il-11rα antibodies
SI4214240T1 (sl) Protitelesa anti-ccr8
UA45074S (uk) 1. навушники
EP4168384A4 (en) THYROMIMETICS
EP4167986A4 (en) THYROMIMETICS
JP1746772S (ja) 引き出し内オーガナイザー
IL310245A (en) Anti-hla-g antibodies
EP4311082A4 (en) COMPONENT
EP4299745A4 (en) ANTI-SARS-COV-2 ANTIBODIES
EP4098693A4 (en) POLYAMIDE COMPOSITION
PT4038149T (pt) Compostos anti-incrustação
EP4121110A4 (en) ANTI-CERAMIDE ANTIBODIES
EP4051451C0 (en) SLIDING CLAMP
EP4342989A4 (en) ANTI-NOROVIRUS ANTIBODIES
UA41453S (uk) Органайзер для речей
EP4321516A4 (en) BISIMIDE PHENOL COMPOUND
IL313590A (en) Compounds
IL313022A (en) Compounds
IL312391A (en) Novel anti-il-36r antibodies